Видео ютуба по тегу B-Cell Maturation Antigen

CAR-T-клетки при лимфоме: обновленная информация с #ASH25 - 17 декабря 2025 г.
CAR-T-клетки при лимфоме: обновленная информация с #ASH25 - 17 декабря 2025 г.
Experts Discuss CELMoD Agents for Treating Multiple Myeloma
Experts Discuss CELMoD Agents for Treating Multiple Myeloma
Immunotherapy of myeloma: A game changer
Immunotherapy of myeloma: A game changer
CDE 102: Молекулярное тестирование при множественной миеломе
CDE 102: Молекулярное тестирование при множественной миеломе
Navigating the Challenges of IgAN Management: Clinical Implications of Emerging B-Cell Therapies
Navigating the Challenges of IgAN Management: Clinical Implications of Emerging B-Cell Therapies
Dr Quazi Smita Haque
Dr Quazi Smita Haque
ASH 2025 Insights: Multiple Myeloma
ASH 2025 Insights: Multiple Myeloma
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Post ASH Webinar - ASH 2025 myeloma highlights
Post ASH Webinar - ASH 2025 myeloma highlights
18. Putting solid tumours under the T-knife: how a next-gen TCR aims to crack them
18. Putting solid tumours under the T-knife: how a next-gen TCR aims to crack them
CAR-T explained. How Your Immune Cells Become Cancer-Killing Machines
CAR-T explained. How Your Immune Cells Become Cancer-Killing Machines
The evolving role of T-cell engagers in myeloma: the MagnetisMM-6 and MELT-MM trials
The evolving role of T-cell engagers in myeloma: the MagnetisMM-6 and MELT-MM trials
Improving access to CAR T-cell therapy for eligible patients
Improving access to CAR T-cell therapy for eligible patients
Bispecific antibodies in myeloma: top trial updates from ASH 2025
Bispecific antibodies in myeloma: top trial updates from ASH 2025
Functional fitness of CAR T-cells in the bone marrow following durcabtagene autoleucel in RRMM
Functional fitness of CAR T-cells in the bone marrow following durcabtagene autoleucel in RRMM
The potential of incorporating sBCMA & MTV data into clinical decision-making
The potential of incorporating sBCMA & MTV data into clinical decision-making
In vivo CAR-T for multiple myeloma: promising findings from a small trial
In vivo CAR-T for multiple myeloma: promising findings from a small trial
Ciara Freeman2
Ciara Freeman2
Corbin Wright, MD: Real-world elranatamab outcomes in relapsed/refractory myeloma
Corbin Wright, MD: Real-world elranatamab outcomes in relapsed/refractory myeloma
Laith Hamed: Autoimmune disease does not worsen BCMA CAR-T safety or outcomes
Laith Hamed: Autoimmune disease does not worsen BCMA CAR-T safety or outcomes
Pharmacology of Ciltacabtagene autoleucel (Carvykti); Mechanism of Action, Uses, Effects
Pharmacology of Ciltacabtagene autoleucel (Carvykti); Mechanism of Action, Uses, Effects
Pharmacology of Idecabtagene vicleucel (Abecma); Mechanism of Action, Uses, Effects
Pharmacology of Idecabtagene vicleucel (Abecma); Mechanism of Action, Uses, Effects
Real-time multimodal AI for early risk prediction in BCMA CAR-T–treated myeloma
Real-time multimodal AI for early risk prediction in BCMA CAR-T–treated myeloma
Francesca Albano, PhD: Low BCMA density drives CAR resistance; SEMA4A CAR rationale in MM
Francesca Albano, PhD: Low BCMA density drives CAR resistance; SEMA4A CAR rationale in MM
Predictive relapse indicators for myeloma T-cell engagers (PRIME) model
Predictive relapse indicators for myeloma T-cell engagers (PRIME) model